CWA
TEVA icon

Clarus Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Clarus Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-218
Closed -$2K – 502
2019
Q2 		$2K Hold
218
– – ﹤0.01% 563
2019
Q1 		$3K Buy
+218
New +$3.84K ﹤0.01% 641

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return

Clarus Wealth Advisors's TEVA Position: Q3 2019 in Review

Clarus Wealth Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2019, closing a stake of 218 shares — an estimated $2K sold.

Clarus Wealth Advisors first reported a position in TEVA in Q1 2019 and held it in 2 quarters. The position peaked at $3K in Q1 2019. 427 funds tracked by Wall St. Rank hold TEVA as of Q3 2019.

  • Clarus Wealth Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Clarus Wealth Advisors sold 218 Teva Pharmaceuticals shares in Q3 2019, an estimated $2K.
  • Clarus Wealth Advisors first reported a position in Teva Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Clarus Wealth Advisors's Teva Pharmaceuticals position peaked at $3K in Q1 2019.
  • 427 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2019.

Based on Clarus Wealth Advisors's 13F filing for Q3 2019, filed 11 Oct 2019.